Stock News Releases and Press Releases OTCMKTS, NASDAQ and NYSE Markets

TBRG - TruBridge Announces Date for Second Quarter 2024 Conference Call

TruBridge (NASDAQ: TBRG), a healthcare solutions company, today announced that it will release its financial results for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, after the market closes. The Company will host a conference call at 4:30 p.m. Eastern Time that same day. T...

IIIV - i3 Verticals Announces Earnings Release and Conference Call Date for Third Quarter of Fiscal 2024

i3 Verticals, Inc. (Nasdaq: IIIV) (“i3 Verticals” or the “Company”), announced today that it will release its financial results for the third quarter ended June 30, 2024, on Thursday, August 8, 2024, after the Nasdaq market close. The Company will also host a confe...

INTU - Intuit Appoints AI Leader Forrest Norrod to its Board of Directors

Norrod, an AMD executive with deep AI expertise, will help accelerate Intuit's AI innovation Intuit Inc. (Nasdaq: INTU), the global financial technology platform that makes Intuit TurboTax , Credit Karma , QuickBooks , and Mailchimp , announced that it appointed Forres...

SNYNF - Press Release: Online availability of Sanofi's half-year financial report for 2024

Online availability of Sanofi’s half-year financial report for 2024 Paris, July 25, 2024 . Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available and has been filed with the French market regulator Autorité des marche�...

PFE - European Commission Approves Pfizer's DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9) after up to four years of follow-up, providing sustained bleed protection and potentially avoiding years of treatment burden with p...